TNFSF11 and osteoporosis: In the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every Six Months (FREEDOM) trial of denosumab, which is a monoclonal antibody that inhibits receptor activator of nuclear factor‐κβ ligand [RANKL]), the median baseline ten‐year fracture risk was 15%.25